-
Snibe received CE List A Certificate for HBV Detection
Shenzhen, China, 26 May 2022-- Snibe has received the CE List A Certificate for 5 MAGLUMI® CLIA immunoassays of Hepatitis B virus (HBV) detection, covering Anti-HBc IgM, Anti-HBs, HBeAg, Anti-HBe, and anti-HBC. Up to now, 6 CLIA immunoassays for HBV detection have all obtained CE List A Certificate, besides the MAGLUMI® HBsAg (CLIA) Assay. -
Snibe Gets CE Mark for COVID-19 Antigen Self-Testing
Recently, Snibe receives the CE mark for its RapisafeTM SARS-CoV-2 Ag test (Colloidal Gold), which further confirmed that the quality of our Self-Testing kits is in line with international standards.
-
Snibe announced a global strategic cooperation with Thermo Fisher Scientific
From August 29th to 31st, 2019, the 15th National Congress of Laboratory Medicine (NCLM 2019), hosted by Chinese Medical Association and Chinese Society of Laboratory Medicine, was held at Suzhou International Expo Centre.
-
Snibe Shines at the WorldLab 2022 in Seoul
WorldLab Seoul 2022, the 24th International Congress of Clinical Chemistry and Laboratory Medicine is held at Coex, Seoul, Korea on 26-30 June 2022, which presents and discusses the latest advances in clinical laboratory diagnosis together with global attendees. -
Snibe Shows Great Charms at EuroMedlab 2022 in Munich
EuroMedlab Munich 2022, the largest exhibition in the field of Clinical Chemistry and Laboratory Medicine in Europe, which attracted more than 2000 participants, was held in ICM International Congress Center from April 10 to 14, 2022.
-
Snibe Showcases Total Lab Automation at MEDLAB 2020
From Feb. 3rd to 6th, Snibe brings the latest product SATLAS-TCA to Medlab Middle East with booth NO.: Z5.C20. in Dubai, United Arab Emirates, one of the largest and most influential medical exhibitions across the world, attracting more than 25,800 professional visitors, providing a great platform for all to share and communicate the recent technology available in the IVD, and medical laboratory market.
